Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon

FDA's Jeffrey Shuren and Janet Woodcock tell a Senate committee that the agency is more concerned with implementing combination product provisions from the 21st Century Cures Act than working on a novel review pathway for device/drug combination products.

Shifting priorities at FDA means work on a specific review pathway for combination products has been superseded by implementation of the combo products provision in the 21st Century Cures Act, agency center directors said at a recent hearing in the Senate.

Testifying before the Senate Health, Education, Labor and Pensions (HELP) Committee on March 21, Device Center Director Jeffrey Shuren told Sen. Sheldon Whitehouse, D-R.I

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Combination Products

More from Device Area